All

Why an Efficacious Drug Therapy for Narcolepsy Is Underused

Low prescribing rates persist even as evidence supports benefit, pointing to missed conversations, unclear expectations, and fragile early treatment periods.

All

The Once-Nightly, Salt-Free, Artificial Sweetener-Free Oxybate in the Works for Narcolepsy, IH

Avadel Pharmaceuticals has licensed valiloxybate from XWPharma Ltd.

All

FDA Expands Approval of LUMRYZ for Pediatric Narcolepsy

The FDA has approved Avadel Pharmaceuticals' LUMRYZ for pediatric patients aged 7 and older with narcolepsy, offering a once-nightly treatment for cataplexy and excessive daytime sleepiness.

Lumryz Reduces Narcolepsy Symptoms, Regardless of Use of Alerting Drugs

Sep 26, 2024 | Narcolepsy

A post-hoc analysis confirmed the efficacy of Lumryz in study participants who were and were not using a stable dose of an alerting agent.

Patient Voices Drive Push for Better Idiopathic Hypersomnia Care

Sep 17, 2024 | Idiopathic Hypersomnia

A new report illuminates the real-world experiences and treatment needs of individuals with idiopathic hypersomnia.

Narcolepsy Patients Prefer Once-Nightly Lumryz Over Twice-Nightly Oxybate

Sep 3, 2024 | Pharmaceuticals

Survey data demonstrate that 94% of people with narcolepsy prefer the once-nightly regimen of Lumryz over twice-nightly oxybate regimens.

Narcolepsy Medication Lumryz Linked to Weight Loss

Aug 20, 2024 | Weight

Nearly one in five study participants treated with the extended-release sodium oxybate medication experienced clinically meaningful weight loss.

Avadel Eyes New Treatment Indications for Narcolepsy Drug Lumryz

Aug 8, 2024 | Pharmaceuticals

Avadel reports advancements for Lumryz, including a phase 3 trial for idiopathic hypersomnia and an upcoming FDA decision on pediatric narcolepsy.

First Patient Dosed in Phase 3 Study of Lumryz for Idiopathic Hypersomnia

Aug 2, 2024 | Idiopathic Hypersomnia

The study will evaluate the efficacy and safety of Lumryz, an extended-release sodium oxybate, as a once-at-bedtime treatment for idiopathic hypersomnia.

Avadel to Present New Data on Lumryz for Narcolepsy at SLEEP 2024

May 22, 2024 | Narcolepsy

Avadel will present a series of new analyses highlighting the efficacy, safety, and patient preference for Lumryz, a once-nightly, extended-release formulation of sodium oxybate.

Avadel Reports Uptick in Lumryz Therapy Adoption for Narcolepsy in Q1

May 13, 2024 | Pharmaceuticals

Patient usage of Lumryz in increased 70% in Q1, while Avadel plans to expand into pediatric treatment and launch a phase 3 trial in idiopathic hypersomnia.

Jazz and Avadel Both Secure Wins in Patent Lawsuit Over Narcolepsy Drug

Mar 5, 2024 | Narcolepsy

A jury from the United States District Court for the District of Delaware delivered a mixed verdict in a patent lawsuit between Jazz Pharmaceuticals Inc and Avadel Pharmaceuticals plc concerning Avadel’s narcolepsy medication Lumryz.

Once-Nightly Lumryz Attracts Over 1,200 Narcolepsy Patients Since June Launch

Mar 4, 2024 | Narcolepsy, Pharmaceuticals

Avadel Pharmaceuticals’ CEO says the “meaningful increase” in patients initiating therapy underscores the unmet need for a once-at-bedtime therapy.

How to Select the Most Suitable Pharmacotherapy for Type 1 Narcolepsy Patients

Jan 26, 2024 | Narcolepsy, Prescription Drugs

Sleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.

Lumryz Gains Ground in Narcolepsy Treatment, Reports Avadel

Jan 10, 2024 | Narcolepsy, Pharmaceuticals

Avadel Pharmaceuticals shared updates on the performance and reception of its new narcolepsy medication, Lumryz, a once-at-bedtime extended-release sodium oxybate medication that has been on the market since June 2023.

Avadel to Present Data Supporting Once-Nightly Lumryz for Narcolepsy

Oct 20, 2023 | Pharmaceuticals

Avadel Pharmaceuticals announced new and encore data abstracts emphasizing the clinical benefit of Lumryz and patient preference for a once-at-bedtime narcolepsy treatment option.

Avadel Prepares to Seek FDA Approval of Lumryz in Pediatric Population

Aug 10, 2023 | Narcolepsy, Pharmaceuticals

Avadel aims to expand the potential of Lumryz with a supplemental New Drug Application filing planned in the second half of 2023 for Lumryz in the pediatric narcolepsy population.